Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.72 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.69 |
| ▸ | NPC1 | O15118 | 5/20 | 0.67 |
| ▸ | RAB9A | P51151 | 5/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.67 |
| ▸ | POLB | P06746 | 2/20 | 0.67 |
| ▸ | MEN1 | O00255 | 2/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.62 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.62 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.62 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.61 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.61 |
| ▸ | PGR | P06401 | 1/20 | 0.61 |
| ▸ | JAK2 | O60674 | 1/20 | 0.59 |
| ▸ | TYK2 | P29597 | 1/20 | 0.59 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24203622 | 0.89 | PTPN1 (0.69) | SIRT1PTPN1NPC1RAB9AKDM4E | |
| SCHEMBL126415 | 0.88 | PTPN1 (0.87) | SIRT1PTPN1NPC1RAB9AKDM4E | |
| SCHEMBL14715824 | 0.86 | NPC1 (0.88) | SIRT1PTPN1NPC1RAB9AKDM4E | |
| SCHEMBL18103163 | 0.86 | NPC1 (0.88) | SIRT1PTPN1NPC1RAB9AKDM4E | |
| SCHEMBL2563371 | 0.85 | NPC1 (0.66) | SIRT1PTPN1NPC1RAB9AKDM4E | |
| SCHEMBL19501815 | 0.84 | SIRT1 (1.00) | SIRT1PTPN1NPC1RAB9AKDM4E | |
| SCHEMBL26953087 | 0.84 | PTPN1 (0.88) | SIRT1PTPN1NPC1RAB9AKDM4E | |
| N-Phenylbenzamide SCHEMBL5402750 | 0.83 | SIRT1 (0.83) | SIRT1PTPN1NPC1RAB9AKDM4E | |
| SCHEMBL24202631 | 0.83 | SIRT1 (0.83) | SIRT1PTPN1NPC1RAB9AKDM4E | |
| N-Phenylbenzamide SCHEMBL31966 | 0.83 | SIRT1 (0.83) | SIRT1PTPN1NPC1RAB9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148531-B2 | Quinoline and quinoxaline derivatives as inhibitors of kinase enzymatic activity | CHROMA THERAPEUTICS LTD. (GB) | 2012-04-03 | — | — | US | disclosed |
| US-8148531-B2 | Quinoline and quinoxaline derivatives as inhibitors of kinase enzymatic activity | CHROMA THERAPEUTICS LTD. (GB) | 2012-04-03 | — | — | US | disclosed |
| US-8148531-B2 | Quinoline and quinoxaline derivatives as inhibitors of kinase enzymatic activity | CHROMA THERAPEUTICS LTD. (GB) | 2012-04-03 | — | — | US | disclosed |
| US-8137447-B2 | Electroless plating solution, method for electroless plating using the same and method for manufacturing circuit board | C. UYEMURA & CO., LTD. (JP) | 2012-03-20 | — | — | US | disclosed |
| EP-1877383-B1 | QUINOLINE AND QUINOXALINE DERIVATIVES AS INHIBITORS OF KINASE ENZYMATIC ACTIVITY | CHROMA THERAPEUTICS LTD (GB) | 2011-09-07 | — | — | EP | disclosed |
| EP-1877383-B1 | QUINOLINE AND QUINOXALINE DERIVATIVES AS INHIBITORS OF KINASE ENZYMATIC ACTIVITY | CHROMA THERAPEUTICS LTD (GB) | 2011-09-07 | — | — | EP | disclosed |
| US-20100003399-A1 | ELECTROLESS PLATING SOLUTION, METHOD FOR ELECTROLESS PLATING USING THE SAME AND METHOD FOR MANUFACTURING CIRCUIT BOARD | C. UYEMURA & CO., LTD. (JP) | 2010-01-07 | — | — | US | disclosed |
| US-20090131461-A1 | Quinoline and quinoxaline derivatives as inhibitors of kinase enzymatic activity | CHROMA THERAPEUTICS LTD. (GB) | 2009-05-21 | — | — | US | disclosed |
| US-20090131461-A1 | Quinoline and quinoxaline derivatives as inhibitors of kinase enzymatic activity | CHROMA THERAPEUTICS LTD. (GB) | 2009-05-21 | — | — | US | disclosed |
| US-20090131461-A1 | Quinoline and quinoxaline derivatives as inhibitors of kinase enzymatic activity | CHROMA THERAPEUTICS LTD. (GB) | 2009-05-21 | — | — | US | disclosed |
| US-6765003-B1 | ANTICARCINOGENIC, ANTITUMOR, AND ANTIMETASTASIS AGENTS; RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, OSTEOPOROSIS, MULTIPLE SCLEROSIS, STROKE, ARTERIOSCLEROSIS, | PHARMACIA ITALIA, SPA (IT) | 2004-07-20 | — | — | US | disclosed |
| EP-1200398-A1 | 3-ARYLSULFONYL-2-(SUBSTITUTED METHYL)PROPANOIC ACID DERIVATES AS MATRIX METALLOPROTEINASE INHIBITORS | Pharmacia Italia S.p.A. (IT) | 2002-05-02 | — | — | EP | disclosed |
| WO-2001005756-A1 | 3-ARYLSULFONYL-2-(SUBSTITUTED METHYL)PROPANOIC ACID DERIVATES AS MATRIX METALLOPROTEINASE INHIBITORS | PHARMACIA & UPJOHN SPA (IT) | 2001-01-25 | — | — | WO | disclosed |
| US-5357010-A | Polymerizing chloroprene in presence of free radical catalyst and chain transfer agent | ENICHEM ELASTOMERES FRANCE SA (FR) | 1994-10-18 | — | — | US | disclosed |
| US-5194539-A | Of ethylenically unsaturated monomers where the aqueous dispersion is free from odor causing xanthogen disulfide | RHONE-POULENC CHIMIE (FR) | 1993-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131461-A1 | Quinoline and quinoxaline derivatives as inhibitors of kinase enzymatic activity | CDK1, AURKC, CSNK1G3 | SIRT1 1893/4885PTPN1 2214/4885NPC1 2449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.